glp-1 obesity drug updates The revolution: What UAB researchers are discovering about how these drugs work Upcoming wave of hormone-based therapies

Smaller companies are especially struggling

The EY-Parthenon analysis projects usage to grow quickly in the coming 10 years to between 13% and 21% of US adults, a total market size of 30 million to 50 million people

The median time from initiation of semaglutide to the most recent HbA1c measurement was 928 days (IQR 2161,343

Additionally, some novel GLP-1s hold promise for improved tolerability, as evidenced by Structure Therapeutics phase 2 data for GSBR-1290, which demonstrated encouraging results in terms of AEs and discontinuation rates

A More Transparent Marketplace As unregulated forms fade, consumers will have clearerand arguably saferchoices

The core dietary principles remain the same regardless of medication: high protein, adequate fiber, controlled calories